Epidemiology Study - Overview

Retinal Vein Occlusion Epidemiology Study Objective:

To determine the prevalence and incidence of retinal vein occlusion among individuals in a defined population. This objective outlines the primary aim of the study, which is to establish the frequency of Retinal vein occlusion within a specific age group and geographic area, while also seeking to understand potential factors contributing to its development. Moreover, the report is having geographic coverage including North America, Europe and rest of the world however customisation can be made in the geographic coverage.

Retinal Vein Occlusion Study USP:

• This epidemiological study on Retinal vein occlusion stands out due to its comprehensive approach in establishing precise prevalence rates, identifying novel risk factors, and exploring geographical variations in a diverse population.
• By integrating advanced imaging techniques with robust statistical analyses, the study aims to provide actionable insights to identify treatment opportunities, target population, and an overview on public health initiatives aimed at mitigating the impact of Retinal vein occlusion related health problems.
• Through meticulous data collection and rigorous methodology, the study not only contributes to the scientific understanding of Retinal vein occlusion but also serves as a foundation for future research events and healthcare policymaking in addressing this increasing Retinal vein occlusion cases.

Retinal Vein Occlusion related Study Overview:

The study Defines Retinal vein occlusion as an advanced form of disease. The significance of studying Retinal vein occlusion epidemiology is due to its increasing prevalence in different age populations.

Retinal Vein Occlusion Study Design:

Population: The target population and the sampling method (e.g., random sampling from healthcare registries or population databases)

Data Collection: Detail methods for identifying Retinal vein occlusion cases (e.g., clinical examination, imaging studies) and demographic data (age, sex, ethnicity).

Retinal Vein Occlusion Epidemiological Parameters:

Prevalence: Prevalence rates considered per 1,000 or 10,000 population.

Incidence: Determine annual incidence rates per 1,000 person-years.

Risk Factors: Analyse associations between Retinal vein occlusion and potential risk factors (e.g., age, genetics).

Geographical Variations: Compare prevalence or incidence rates across different regions or countries.                        

Retinal Vein Occlusion study summary:

Retinal vein occlusion study summarizes the prevalence, incidence, possible risk factors, and geographic variations of the Retinal vein occlusion worldwide.

Retinal Vein Occlusion overview:

Retinal Vein Occlusion (RVO) is a vascular disorder of the eye that occurs when vein carrying blood away from retina becomes blocked causing impaired blood flow, retinal haemorrhages, swelling. This blockage can cause sudden, painless, vision loss or distortion, depending on severity and location of the occlusion.

Retinal vein occlusion (RVO) based on anatomic location of the occlusion is segmented into retinal vein occlusion (BRVO), central retinal vein occlusion (CRVO), and hemiretinal vein occlusion (HRVO).

In Australia, the 5-year incidence of any RVO was 1.0%, and the 10-year incidence was 1.6%. These rates are similar to those in the United States, where the 5-year incidence was 0.8% and the 15-year incidence was 2.3%. In Japan, the 9-year incidence was slightly higher at 2.0%.

Treatments options available for RVO include Laser Therapy, Intravitreal Injections, Surgery. Key market players involved in manufacturing of therapeutics for RVO are Shire, Astellas Pharm, Santen Pharmaceutical, Zymeworks, Regeneron Pharmaceuticals, Ipsen, NantKwest, Horizon Therapeutics, Genentech, Bayer, Ohr Pharmaceutical, Allergan, Aerie Pharmaceuticals, Roche, Novartis.

April 2025, Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA HD (aflibercept) Injection 8 mg. This application seeks approval for the treatment of macular edema following retinal vein occlusion (RVO) and for monthly dosing across all approved indications. If approved, EYLEA HD would be the first treatment for RVO with an 8-week dosing schedule after an initial monthly period, potentially reducing the number of injections needed compared to other anti-VEGF therapies.

Retinal Vein Occlusion Demographic and Environmental Risk Factors:

Age and Sex: According to one of the Korean nationwide study, the prevalence was 0.6% among adults aged 19 or more and increased to 0.1 % in those aged 40 and more years. CRVO was rare in individuals under 60 years, and RVO was rarely observed in participants younger than 40 years. As per Gutenberg Health Study published in ScienceDirect, Men were found to be 1.7 times more frequently affected by RVO than women and the prevalence was 0.2% in individuals with 35-44 and 45-54 years, 0.48% in people aged 55 to 64 years, o.92% in those aged 65 to 74 years.

Ethnicity: According to one of the reported in PubMed Central age and sex standardised prevalence among different ethnic groups were as follows; 3.7 per 1000 in whites, 3.9 per 1000 in blacks, 5.7 per 1000 in Asians, 6.9 per 1000 in Hispanics.

Risk Factors causing Retinal Vein Occlusion: Family history of vascular disease, Age, Atherosclerosis including hyperlipidaemia, hypertension, diabetes, then open-angle glaucoma, inflammatory conditions like sarcoidosis and Lyme disease, hypercoagulable states such as smoking, OCP, pregnancy, malignancy, sickle cell disease are some of the risk factors which can cause the Retinal Vein Occlusion.

Retinal Vein Occlusion Market Scope:

Drivers: Increasing Prevalence of Retinal Vein Occlusion

The global prevalence of retinal vein occlusion (RVO) is experiencing a significant rise, primarily due to the aging population and increasing incidence of risk factors such as hypertension, diabetes, and obesity. As individuals age, the risk of developing eye-related conditions, including RVO, escalates. This trend necessitates the expansion of treatment options and healthcare services, thereby driving the Retinal Vein Occlusion Market Industry forward. As more individuals are diagnosed with RVO, the demand for effective therapeutic solutions rises, fostering innovation and investment within this sector. The development of advanced imaging techniques contributing to better diagnosis and management of RVO is another driving factor.

Technological Advancements in Treatment

Technological innovations play a crucial role in the growth of the Retinal Vein Occlusion Market Industry. The development of new therapeutic agents and treatment modalities, including anti-VEGF (Vascular Endothelial Growth Factor) injections and corticosteroids, has greatly improved patient outcomes. Advanced medical devices such as optical coherence tomography (OCT) have enhanced the precision of diagnoses, enabling earlier interventions that may prevent severe vision loss. Minimally invasive procedures are also becoming increasingly popular, appealing to both healthcare professionals and patients alike due to the reduced recovery time and lower risk of complications. As research continues to yield novel treatment options, the market is expected to witness a surge in effective therapies aimed at tackling retinal vein occlusion.

Restraints: High treatment cost, limited access to the treatments in the developing countries, side effects of the treatment, strict regulatory framework leading to delayed product launch are some of the factors which can hamper the growth of the market.